A5063538935- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Parkinson's Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Cholinesterase and Neurodegenerative Diseases
- Pneumonia and Respiratory Infections
- Nosocomial Infections in ICU
- S100 Proteins and Annexins
- Neurological Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Advanced Glycation End Products research
- Hearing Loss and Rehabilitation
- Natural Antidiabetic Agents Studies
- Hearing, Cochlea, Tinnitus, Genetics
- Neurological Disorders and Treatments
- Ginkgo biloba and Cashew Applications
- Neuroscience and Neuropharmacology Research
- Functional Brain Connectivity Studies
- Aging, Health, and Disability
- Vitamin D Research Studies
- Noise Effects and Management
- Medicinal Plants and Neuroprotection
- Mind wandering and attention
- Cognitive Functions and Memory
- Information Architecture and Usability
Hospital Clínico de la Universidad de Chile
2016-2025
University of Chile
2014-2024
Hospital Universitário Gaffrée e Guinle
2024
Universidade Federal do Estado do Rio de Janeiro
2024
Universidade Federal Fluminense
2024
Universidad Técnica de Manabí
2023
Advanced Center for Chronic Diseases
2020-2022
Pontificia Universidad Católica de Valparaíso
2015
Pontificia Universidad Católica de Chile
2002-2005
Hyperinsulinemia as well type II diabetes mellitus are among the risk factors for Alzheimer's disease (AD). However, molecular and cellular basis that link insulin resistance disorders with AD far from clear. Here, we discuss potential mechanisms may explain participation of these metabolic in pathogenesis AD. The human brain uses glucose a primary fuel; secreted by pancreas cross blood-brain barrier (BBB), reaching neurons glial cells, exerts region-specific effect on metabolism. Glucose...
Abstract Across Latin American and Caribbean countries (LACs), the fight against dementia faces pressing challenges, such as heterogeneity, diversity, political instability, socioeconomic disparities. These can be addressed more effectively in a collaborative setting that fosters open exchange of knowledge. In this work, Consortium on Dementia (LAC‐CD) proposes an agenda for integration to deliver Knowledge Action Framework (KtAF). First, we summarize evidence‐based strategies (epidemiology,...
Platelets are a major peripheral reservoir of the amyloid-β protein precursor, so they have been considered as potential biological marker Alzheimer's disease (AD). Here, it is demonstrated that tau also present in platelets and
Abstract Objective. The differential diagnosis of behavioral variant frontotemporal dementia (bvFTD) and Alzheimer’s disease (AD) remains challenging in underrepresented, underdiagnosed groups, including Latinos, as advanced biomarkers are rarely available. Recent guidelines for the study highlight critical role biomarkers. Thus, novel cost-effective complementary approaches required clinical settings. Approach . We developed a framework based on gradient boosting machine learning...
Abstract Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported survey to explore the ongoing work, needs, interests, potential barriers, opportunities for future studies related biomarkers. The results show that neuroimaging is most used biomarker (73%), followed by genetic (40%), peripheral fluids (31%), cerebrospinal fluid (29%). Regarding barriers LAC, lack of funding appears undermine implementation clinical...
Age and sex are known risk factors for Parkinson's Disease (PD), but it remains controversial if there differences in the diagnosis latency. The objective of this study was to examine these Latin America. American Research Consortium on Genetics PD (LARGE-PD) includes patients from countries across America who were diagnosed using UK Brain Bank criteria. Ages at onset (AAO; N = 2,792), (AAD; 1,416), calculated latency (N 1,416) extracted LARGE-PD database compared both males females overall,...
Platelets are major reservoirs of circulating amyloid-β and protein precursor (AβPP) have been postulated as a reliable source for biological markers Alzheimer's disease (AD). We recently demonstrated that tau is also present in
Intracellular neurofibrillary tangles are part of the core pathology Alzheimer's disease (AD), which mainly composed hyperphosphorylated tau protein.The purpose this study is to determine whether high molecular weight (HMW) or low (LMW) protein levels, as well ratio HMW/LMW, present in platelets correlates with brain magnetic resonance imaging (MRI) structural changes normal and cognitively impaired subjects.We examined 53 AD patients 37 subjects recruited from two Memory Clinics at...
A 68-years-old Hispanic man, complained of night sweats, low grade fewer, unexplained weight loss, and memory problems over 3 months. Abdominal tomography showed multiple intra-abdominal adenopathy biopsy confirmed classic Hodgkin's lymphoma. He commenced treatment with chemotherapy. Three months later, he had acute onset inattention, auditory hallucinations alterations anterograde memory. The patient developed psychomotor agitation, unresponsive to a combination neuroleptics...
Background: In relapsing-remitting multiple sclerosis, no evidence of disease activity-3 (NEDA-3) is defined as relapses, disability progression and MRI activity. NEDA-4 status meeting all NEDA-3 criteria plus having an annualized brain volume loss (a-BVL) ≤0.4%. Prospective real-world studies presenting data on are scarce. Objective: To determine the proportion patients failing to meet one or more contribution each component this failure. Methods: Forty-eight were followed for 12 months....
Clinically-evaluated nutraceuticals are candidates for Alzheimer's disease (AD) prevention and treatment. Phase I studies showed biological safety of the nutraceutical BrainUp-10®, while a pilot trial demonstrated efficacy Cell neuroprotection. BrainUp-10® blocks tau self-assembly. Apathy is most common behavioral alterations.The aim was to explore in mitigating cognitive symptoms providing life quality, cohort Chilean patients with mild moderate AD.The multicenter, randomized, double blind,...
The establishment of a molecular biomarker for early detection Alzheimer’s disease (AD) is critical diagnosis and follow up patients, as quantitative parameter in the evaluation potential new drugs to control AD. A list blood biomarkers has been reported but none validated clinic. changes hyperphosphorylated tau amyloid peptide cerebrospinal fluid currently used tool clinics research purposes, this method highly invasive. Recently, we non-invasive reliable that correlates increase ratio...
Age-related hearing loss is an important risk factor for cognitive decline. However, audiogram thresholds are not good estimators of dementia in subjects with normal or mild loss. Here we propose to use distortion product otoacoustic emissions (DPOAEs) as objective and sensitive tool estimate the decline older adults